MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.1226
https://www.valueinhealthjournal.com/article/S1098-3015(22)01427-9/fulltext
Title :
MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01427-9&doi=10.1016/j.jval.2022.04.1226
First page :
Section Title :
Open access? :
No
Section Order :
11098